stockportfolio.pro
Stocks / ABT vs CERT
ABT vs CERT
Abbott Laboratories and Certara, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | Certara, Inc. (CERT) | |
|---|---|---|
| Market cap | $158.9B | $0.8B |
| Revenue (latest FY) | $44.33B | $418.84M |
| Net income (latest FY) | $6.52B | $-1.59M |
| Revenue growth (5y CAGR) | 5.1% | 11.5% |
| Net margin | 14.7% | -0.4% |
| Return on equity | 12.5% | -0.2% |
| P/E ratio | 25.3 | — |
| Dividend yield | 2.8% | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open CERT — freeFrequently asked questions
Which is bigger, ABT or CERT?
Abbott Laboratories is larger by market capitalization — $158.9B versus $0.8B.
Which grows faster, ABT or CERT?
Over the last five fiscal years, Certara, Inc. grew revenue faster — 11.5%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.